India's first indigenous bird flu vaccine for poultry to be unveiled on Nov 20
Synopsis
Key Takeaways
Bhopal-based ICAR-National Institute of High Security Animal Diseases (ICAR-NIHSAD) has developed India's first indigenous vaccine against Highly Pathogenic Avian Influenza (HPAI), commonly known as bird flu, officials confirmed on Wednesday, 18 November 2026. The vaccine targets the H5N1 Clade 2.3.2.1a strain — the subtype responsible for most poultry outbreaks in India — and fills a critical gap that has left the country's ₹3 lakh crore poultry sector without strain-specific protection for over two decades.
Landmark Unveiling on November 20
Union Minister of Agriculture and Farmers Welfare and Rural Development Shivraj Singh Chouhan will formally dedicate the 'indigenous inactivated H5N1 HPAI virus vaccine' for poultry to the nation on 20 November 2026 at the ICAR-NIHSAD campus in Bhopal. The event marks the first time India has produced a domestically developed, commercially viable vaccine against the circulating avian influenza strain, reducing dependence on imported formulations that did not specifically target the dominant local clade.
The Scale of the Threat
Bird flu poses an acute risk to poultry: outbreaks of Highly Pathogenic Avian Influenza can cause up to 100 per cent mortality among infected flocks, triggering mass culling, trade restrictions, and severe disruption to poultry product prices. Since the disease was first detected in India in 2006, the country has recorded more than 500 combined outbreaks of the H5N1 and H5N8 subtypes.
The economic consequences are well-documented. The 2006 outbreak alone resulted in estimated direct and indirect losses of ₹2,200 crore to ₹3,000 crore. A separate outbreak in Manipur caused losses equivalent to 0.5 per cent of the state's GDP. Official estimates warn that an unchecked major outbreak could reduce India's overall GDP growth by 1.5 per cent and put more than 20 per cent of the national poultry population at risk.
Public Health Dimension
The significance of the vaccine extends well beyond agriculture. According to the World Health Organization (WHO), 1,003 human cases of H5N1 avian influenza — resulting in 479 deaths — have been reported across 25 countries, including India, since 2003. Virological studies confirm that the H5N1 Clade 2.3.2.1a strain has driven most chicken outbreaks in recent years, with the virus also detected in mammals and linked to three reported human cases in India. By cutting transmission at the poultry level, the vaccine is expected to reduce zoonotic spillover risk — the pathway through which animal viruses can jump to humans.
Why This Vaccine Is Different
Until now, no specific commercial vaccine was available globally to protect poultry against the circulating Clade 2.3.2.1a strain. ICAR-NIHSAD's formulation directly addresses this gap. The inactivated vaccine is designed to minimise economic losses for poultry farmers and interrupt the chain of transmission from chickens to other animals and, critically, to humans. This comes amid growing international concern over H5N1's pandemic potential, with the WHO and several national health agencies closely monitoring mammalian infections reported in 2024 and 2025.
What Comes Next
The formal dedication on 20 November is expected to be followed by regulatory and rollout discussions for field deployment. Industry bodies and state animal husbandry departments are likely to play a central role in vaccination logistics, particularly in high-risk states that have historically recorded the most outbreaks. The development positions India as one of the few countries to hold an indigenous, strain-matched HPAI vaccine — a strategic asset in both biosecurity and trade diplomacy.